Fibroblast Growth Factor 23: Potential Marker of Invisible Heart Damage in Diabetic Population
Two-dimensional speckle-tracking echocardiography (2DSTE) detects myocardial dysfunction despite a preserved left ventricular ejection fraction. Fibroblast growth factor 23 (FGF23) has become a promising biomarker of cardiovascular risk. This study aimed to determine whether FGF23 may be used as a m...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/6/1523 |
| _version_ | 1797595983295545344 |
|---|---|
| author | Anna Kurpas Karolina Supel Paulina Wieczorkiewicz Joanna Bodalska Duleba Marzenna Zielinska |
| author_facet | Anna Kurpas Karolina Supel Paulina Wieczorkiewicz Joanna Bodalska Duleba Marzenna Zielinska |
| author_sort | Anna Kurpas |
| collection | DOAJ |
| description | Two-dimensional speckle-tracking echocardiography (2DSTE) detects myocardial dysfunction despite a preserved left ventricular ejection fraction. Fibroblast growth factor 23 (FGF23) has become a promising biomarker of cardiovascular risk. This study aimed to determine whether FGF23 may be used as a marker of myocardial damage among patients with diabetes mellitus type 2 (T2DM) and no previous history of myocardial infarction. The study enrolled 71 patients with a median age of 70 years. Laboratory data were analyzed retrospectively. Serum FGF23 levels were determined using a sandwich enzyme-linked immunosorbent assay. All patients underwent conventional echocardiography and 2DSTE. Baseline characteristics indicated that the median time elapsed since diagnosis with T2DM was 19 years. All subjects were divided into two groups according to left ventricular diastolic function. Individuals with confirmed left ventricular diastolic dysfunction had significantly lower levels of estimated glomerular filtration rate and higher values of hemoglobin A1c. Global circumferential strain (GCS) was reduced in the majority of patients. Only an epicardial GCS correlated significantly with the FGF23 concentration in all patients. The study indicates that a cardiac strain is a reliable tool for a subtle myocardial damage assessment. It is possible that FGF23 may become an early diagnostic marker of myocardial damage in patients with T2DM. |
| first_indexed | 2024-03-11T02:45:05Z |
| format | Article |
| id | doaj.art-c3c9d41898964accb427244f01e947c6 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-11T02:45:05Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-c3c9d41898964accb427244f01e947c62023-11-18T09:24:33ZengMDPI AGBiomedicines2227-90592023-05-01116152310.3390/biomedicines11061523Fibroblast Growth Factor 23: Potential Marker of Invisible Heart Damage in Diabetic PopulationAnna Kurpas0Karolina Supel1Paulina Wieczorkiewicz2Joanna Bodalska Duleba3Marzenna Zielinska4Department of Interventional Cardiology, Medical University of Lodz, 251 Pomorska Street, 92-213 Lodz, PolandDepartment of Interventional Cardiology, Medical University of Lodz, 251 Pomorska Street, 92-213 Lodz, PolandDepartment of Interventional Cardiology, Medical University of Lodz, 251 Pomorska Street, 92-213 Lodz, PolandDiabetes Outpatient Clinic ‘Poradnia Nowa’, 90-631 Lodz, PolandDepartment of Interventional Cardiology, Medical University of Lodz, 251 Pomorska Street, 92-213 Lodz, PolandTwo-dimensional speckle-tracking echocardiography (2DSTE) detects myocardial dysfunction despite a preserved left ventricular ejection fraction. Fibroblast growth factor 23 (FGF23) has become a promising biomarker of cardiovascular risk. This study aimed to determine whether FGF23 may be used as a marker of myocardial damage among patients with diabetes mellitus type 2 (T2DM) and no previous history of myocardial infarction. The study enrolled 71 patients with a median age of 70 years. Laboratory data were analyzed retrospectively. Serum FGF23 levels were determined using a sandwich enzyme-linked immunosorbent assay. All patients underwent conventional echocardiography and 2DSTE. Baseline characteristics indicated that the median time elapsed since diagnosis with T2DM was 19 years. All subjects were divided into two groups according to left ventricular diastolic function. Individuals with confirmed left ventricular diastolic dysfunction had significantly lower levels of estimated glomerular filtration rate and higher values of hemoglobin A1c. Global circumferential strain (GCS) was reduced in the majority of patients. Only an epicardial GCS correlated significantly with the FGF23 concentration in all patients. The study indicates that a cardiac strain is a reliable tool for a subtle myocardial damage assessment. It is possible that FGF23 may become an early diagnostic marker of myocardial damage in patients with T2DM.https://www.mdpi.com/2227-9059/11/6/1523fibroblast growth factor 23two-dimensional speckle-tracking echocardiographyleft ventricular diastolic dysfunctiondiabetes mellitus |
| spellingShingle | Anna Kurpas Karolina Supel Paulina Wieczorkiewicz Joanna Bodalska Duleba Marzenna Zielinska Fibroblast Growth Factor 23: Potential Marker of Invisible Heart Damage in Diabetic Population Biomedicines fibroblast growth factor 23 two-dimensional speckle-tracking echocardiography left ventricular diastolic dysfunction diabetes mellitus |
| title | Fibroblast Growth Factor 23: Potential Marker of Invisible Heart Damage in Diabetic Population |
| title_full | Fibroblast Growth Factor 23: Potential Marker of Invisible Heart Damage in Diabetic Population |
| title_fullStr | Fibroblast Growth Factor 23: Potential Marker of Invisible Heart Damage in Diabetic Population |
| title_full_unstemmed | Fibroblast Growth Factor 23: Potential Marker of Invisible Heart Damage in Diabetic Population |
| title_short | Fibroblast Growth Factor 23: Potential Marker of Invisible Heart Damage in Diabetic Population |
| title_sort | fibroblast growth factor 23 potential marker of invisible heart damage in diabetic population |
| topic | fibroblast growth factor 23 two-dimensional speckle-tracking echocardiography left ventricular diastolic dysfunction diabetes mellitus |
| url | https://www.mdpi.com/2227-9059/11/6/1523 |
| work_keys_str_mv | AT annakurpas fibroblastgrowthfactor23potentialmarkerofinvisibleheartdamageindiabeticpopulation AT karolinasupel fibroblastgrowthfactor23potentialmarkerofinvisibleheartdamageindiabeticpopulation AT paulinawieczorkiewicz fibroblastgrowthfactor23potentialmarkerofinvisibleheartdamageindiabeticpopulation AT joannabodalskaduleba fibroblastgrowthfactor23potentialmarkerofinvisibleheartdamageindiabeticpopulation AT marzennazielinska fibroblastgrowthfactor23potentialmarkerofinvisibleheartdamageindiabeticpopulation |